BHST trades 261.0% below Wall Street's consensus target of $10.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BHST achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, BioHarvest Sciences Inc. Common Stock (BHST) has a Wall Street consensus price target of $10.00, based on estimates from 1 covering analysts. With the stock currently trading at $2.77, this represents a potential upside of +261.0%. The company has a market capitalization of $48M.
Analyst price targets range from a low of $10.00 to a high of $10.00, representing a 0% spread in expectations. The median target of $10.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BHST trades at a trailing P/E of -4.6x. Analysts expect EPS to grow +73.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NXRTNexPoint Residential Trust, Inc. | $727M | $28.63 | $27.00 | -5.7% | Hold | — | 10 |
GFAIGuardforce AI Co., Limited | $9M | $0.40 | — | — | — | — | — |
SIGASIGA Technologies, Inc. | $281M | $3.92 | — | — | Buy | 2.3x | 1 |
XTLBXTL Biopharmaceuticals Ltd. | $259659 | $2.36 | — | — | — | — | — |
LWAYLifeway Foods, Inc. | $449M | $29.39 | $35.00 | +19.1% | Buy | 26.5x | 7 |
HALOHalozyme Therapeutics, Inc. | $8.9B | $74.96 | $88.25 | +17.7% | Buy | 9.2x | 27 |
BYFCBroadway Financial Corporation | $96M | $10.38 | — | — | — | — | — |
EDBLEdible Garden AG Incorporated | $1M | $0.16 | — | — | — | — | — |
GRWGGrowGeneration Corp. | $83M | $1.38 | $4.17 | +202.2% | Buy | — | 12 |
IIPRInnovative Industrial Properties, Inc. | $1.8B | $62.93 | $84.67 | +34.5% | Hold | 14.7x | 11 |
Quick answers to the most common questions about buying BHST stock.
The consensus Wall Street price target for BHST is $10, representing 261.0% upside from the current price of $2.77. With 1 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BHST has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $10 implies 261.0% upside from current levels.
BHST's current price is $2.77 with a consensus target of $10 (261.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $10 for BHST, while the most conservative target is $10. The consensus of $10 represents the median expectation. These targets typically reflect 12-month expectations.
BHST is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BHST stock forecast based on 1 Wall Street analysts shows a consensus price target of $10, with estimates ranging from $10 (bear case) to $10 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on BHST, with a "Buy" consensus rating and $10 price target (261.0% upside). 1 of 1 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BHST analyst price targets range from $10 to $10, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.